Pulmonology

The FDA ban yesterday on Juul vaping devices and nicotine e-liquid pods drew praise from the American Medical Association, American Thoracic Society, American Lung Association, among others.

New findings suggest that HIIT may be an effective aerobic exercise option for asthma patients.

The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.

ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.

ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.

The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.

Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.

Higher blood eosinophils, younger age, and eosinophilic chronic rhinosinusitis were among factors associated with a switch from initial biologic therapy in a new study.

The FDA has approved the first generic budesonide and formoterol fumarate dihydrate inhalation aerosol for the treatment of asthma and COPD.

AAAAI 2022: Mepolizumab found effective in standard clinical care regardless of type 2 eosinophil biomarker status in patients with severe asthma.

Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.

AAAAI late-breaking science and findings that could change your treatment plan for patients with severe asthma, summarized by our editors for easy access.

AAAAI 2022: New study found patients with eosinophilic esophagitis who received dupilumab experienced clinically meaningful improvements in symptoms.

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Patients with asthma who did require hospitalization for SARS-CoV-2 infection were at greater risk for intubation and remdesivir treatment, a new study reports.

New study findings on asthma exacerbation risk prediction, rapid steroid reduction, and patient perception of disease lead this quick quiz.

In the majority of studies that reported racial/ethnic data, White participants were highly overrepresented and Black/Hispanic/all Other underrepresented.

Patients with severe, uncontrolled asthma given tezepelumab experienced a reduction in asthma symptomatic days, found a new analysis of the NAVIGATOR trial.

Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.

Tezepelumab significantly reduced exacerbations that required hospitalization or an emergency department visit in a new analysis of patients with moderate-to-severe, uncontrolled asthma.

New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.

New data from the phase 3 NAVIGATOR trial found tezepelumab treatment reduced inflammatory biomarkers of severe, uncontrolled asthma in as little as 2 weeks.

Adults with asthma who had a prior hospitalization or required 2 or more courses of oral corticosteroids were at increased risk of poor COVID-19 outcomes, according to a new study.

New data from the phase 3 NAVIGATOR trial demonstrate superior efficacy of tezepelumab to reduce asthma exacerbations in severe disease year round.